ω-3 Fatty Acids in Pediatric Major Depressive Disorder: A Randomized Clinical Trial

Area of Science:

• Pediatric Psychiatry
• Nutritional Neuroscience
• Clinical Trials

Background:

• Meta-analyses on omega-3 fatty acids for depression yield inconsistent results.
• Evidence regarding omega-3 fatty acids in pediatric depression is limited.
• The promotion of unproven supplements may hinder evidence-based care for pediatric depression.

Purpose of the Study:

• To evaluate the efficacy of adjunctive omega-3 fatty acid supplementation in treating moderate-to-severe pediatric major depressive disorder (MDD).

Main Methods:

• A multicenter, double-blind, placebo-controlled randomized clinical trial.
• 257 youths with MDD received either 1.5 g/d omega-3 fatty acids (EPA:DHA, 2:1 ratio) or placebo, combined with standardized psychotherapy.
• Follow-up was conducted for 36 weeks, with intention-to-treat analysis.

Main Results:

• No significant difference in the trajectory of Children's Depression Rating Scale-Revised (CDRS-R) scores between the omega-3 and placebo groups at 36 weeks.
• Secondary outcomes, including response and remission rates, as well as suicidality, showed no significant between-group differences.
• Adherence was confirmed by increased omega-3 index levels in the supplemented group; no causal relationship was found between study medication and adverse events.

Conclusions:

• Adjunctive omega-3 fatty acid supplementation (1.5 g/d EPA:DHA, 2:1) did not demonstrate superiority over placebo for youths with MDD.
• Future research should investigate EPA-enriched formulations and biomarker-guided approaches for pediatric depression.
• The findings underscore the need for rigorous evaluation of supplements in pediatric mental health.